Esperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $23,917.39 in Stock

Esperion Therapeutics, Inc. (NASDAQ:ESPR) General Counsel Benjamin Looker sold 6,517 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total transaction of $23,917.39. Following the sale, the general counsel directly owned 385,905 shares of the company’s stock, valued at $1,416,271.35. This represents a 1.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Esperion Therapeutics Trading Up 3.4%

Shares of Esperion Therapeutics stock opened at $3.93 on Friday. Esperion Therapeutics, Inc. has a twelve month low of $0.69 and a twelve month high of $4.13. The firm has a market capitalization of $939.51 million, a PE ratio of -7.86 and a beta of 1.01. The firm’s 50-day moving average price is $3.21 and its 200 day moving average price is $2.32.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The business had revenue of $87.31 million during the quarter, compared to analyst estimates of $78.33 million. On average, sell-side analysts predict that Esperion Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ESPR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Wednesday, October 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Piper Sandler initiated coverage on shares of Esperion Therapeutics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, September 19th. Finally, Citigroup restated a “market outperform” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Esperion Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $7.20.

Institutional Investors Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ESPR. North Star Investment Management Corp. purchased a new position in Esperion Therapeutics during the second quarter worth about $25,000. DHJJ Financial Advisors Ltd. grew its stake in shares of Esperion Therapeutics by 209.2% in the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 6,380 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at approximately $25,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $29,000. Finally, R Squared Ltd purchased a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at approximately $33,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.